According to Intercept Pharmaceuticals
's latest financial reports the company has $0.32 B in cash and cash equivalents.
A companyโs cash on hand also refered as cash/cash equivalents (CCE) and Short-term investments, is the amount of accessible money a business has.
Year | Cash on Hand | Change |
---|---|---|
2022-12-31 | $0.49 B | 14.33% |
2021-12-31 | $0.42 B | -10.01% |
2020-12-31 | $0.47 B | -27.41% |
2019-12-31 | $0.65 B | 50.71% |
2018-12-31 | $0.43 B | 5.12% |
2017-12-31 | $0.41 B | -39.81% |
2016-12-31 | $0.68 B | 9.77% |
2015-12-31 | $0.62 B | 161.99% |
2014-12-31 | $0.23 B | 65.43% |
2013-12-31 | $0.14 B | 31.5% |
2012-12-31 | $0.11 B | 522.3% |
2011-12-31 | $17.7 M |
Company | Cash on Hand | differencediff. | Country |
---|---|---|---|
Eli Lilly LLY | $2.92 B | 807.21% | ๐บ๐ธ USA |
Gilead Sciences GILD | $7.26 B | 2,150.91% | ๐บ๐ธ USA |
Bristol-Myers Squibb BMY | $12.28 B | 3,705.23% | ๐บ๐ธ USA |
MediciNova MNOV | $50.99 M | -84.20% | ๐บ๐ธ USA |